Research ArticleOriginal Research
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca, Ricardo Alvarado-Ruiz, Denis Raccah, Gabor Boka, Patrick Miossec, John E. Gerich, on behalf of the EFC6018 GetGoal-Mono Study Investigators
DOI: 10.2337/dc11-1935 Published 1 June 2012
